A low dose of ketamine infusion for acute and maintenance treatment for severe depression and suicide: a double-blind, randomized-controlled study.

A low dose of ketamine infusion for acute and maintenance treatment for severe depression and suicide: a double-blind, randomized-controlled study. - A low dose of ketamine infusion for acute and maintenance treatment for severe depression and suicide.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033760

Enrollment

Registered

2018-08-15

Start date

2018-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment-resistant depression, TRD

Interventions

Ketamine 0.5mg/kg Midazolam 0.045mg/kg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: diagnosis of major depressive disorder according to Diagnostic and Statistical Manual of Mental Disorders-IV-Text Revision (DSM-IV-TR)

Exclusion criteria

Exclusion criteria: 1) Use of CNS intoxicant within the previous 24 hours or urine toxicology screen positive for drugs of abuse 2) Overdose, within previous 24 hours, of any agent which would compromise ketamine metabolism 3) Symptoms of substance abuse/dependence(except nicotine dependence) within 6 months 4) Lifetime use of ketamine or phencyclidine(PCP) 5) Diagnosis of psychosis or bipolar disorder

Design outcomes

Primary

Measure	Time frame
Decreasing rate of suicide symptom postinfusion of ketamine	—

Countries

Asia(except Japan)

Contacts

Public ContactTung-Ping Su

CHENG HSIN GENERAL HOSPITAL Department of Psychiatry

tomsu0402@gmail.com02-28264400

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026